Vice president, oncology early development, AbbVie
Appears in 1 story
Last updated Oct 27, 2026
Leading early development of Temab-A
The FDA granted AbbVie's experimental cancer drug Temab-A two breakthrough therapy designations on October 7, one for colorectal cancer and one for non-small cell lung cancer. The designations speed development and review for drugs that show early evidence of substantial improvement over existing treatments.
Updated Oct 27
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
